The short version of GABA-A receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
=== Penicillin structure === In 1945, Hodgkin and her colleagues, including biochemist Barbara Low, solved the structure of penicillin, demonstrating, contrary to scientific opinion at the time, that it contains a β-lactam ring. The work was not published until 1949.
== Afferent inputs == The PVN receives afferent inputs from many brain regions and different parts of the body, by hormonal control. Among these, inputs from neurons in structures adjacent to the anterior wall of the third ventricle (the "AV3V region") carry information about the electrolyte composition of the blood, and about circulating concentrations of such hormones as angiotensin and relaxin, to regulate the magnocellular neurons. Inputs from the brainstem (the nucleus of the solitary tract) and the ventrolateral medulla carry information from the heart and stomach. Inputs from the hippocampus to the CRH neurones are important regulators of stress responses. Inputs from neuropeptide Y-containing neurons in the arcuate nucleus coordinate metabolic regulation (via TRH secretion) with regulation of energy intake. Specifically, the projections from the arcuate nucleus seem to exert their effect on appetite via MC4R-expressing oxytocinergic cells of the PVN. Inputs from suprachiasmatic nucleus about levels of lighting (circadian rhythms). Inputs from glucose sensors within the brain stimulate release of vasopressin and corticotropin-releasing hormone from parvocellular neurosecretory cells.
==== Milestones of 1,500 RBI, 1,500 runs scored and 200 stolen bases (2004) ==== When he hit his sixth career grand slam against Milwaukee on April 9, 2004, Bagwell tied a club record. He recorded his 200th career stolen base on August 30 against Cincinnati to become the tenth player in MLB history to reach that plateau while hitting 400 home runs. On September 18, 2004, Bagwell collected his 1,500th career RBI with a single in the third inning against the Brewers. Two innings later, he homered for his 1,500th run scored, becoming just the 29th player in MLB history and the first Astro to reach both milestones. Bagwell finished with 27 home runs, stopping a streak of eight consecutive seasons with at least 30, but extending a streak of 12 with at least 20. The Astros faced the Braves in the playoffs for the fourth time in Bagwell's career in the 2004 NLDS. In Game 3, on October 7, he hit his first career postseason home run off Mike Hampton in the first inning in a 4–2 extra-inning loss. After three failed attempts to advance past the first round of the playoffs earlier in Bagwell's career, losing to Atlanta in 1997, 1999, and 2001, and seven overall in 43 years of franchise history, the Astros defeated the Braves for their first-ever playoff series win. The quartet dubbed the "Killer B's," this time including Carlos Beltrán and Lance Berkman, ignited the Astros' offense, batting .395 (34-for-86) with eight home runs, 21 RBI and 24 runs scored. The Astros scored an NLDS-record 36 runs in all and Bagwell batted .318 with two home runs and five RBI.
=== L-Deprenyl === L-Deprenyl, sold under the brand name anipryl, does not target cortisol production, instead it directly addresses the tumour. Research on L-Deprenyl has shown that adrenocorticotropic hormone secretion in the intermediate area of the pituitary gland is controlled by the neurotransmitter dopamine. High levels of dopamine production will shut down adrenocorticotropic hormone secretion. L-Deprenyl inhibits the enzymes responsible for the degradation of dopamine as well as stimulating the production of dopamine. Approximately 5% of dogs experience minor nausea, restlessness, and reduced hearing ability. The different mechanism of L-Deprenyl and that it breaks down into amphetamine and methamphetamine—which suppresses hunger— meaning the normal monitoring tests are not useful in dogs treated with L-Deprenyl. Independent studies showed roughly 20% of dogs to improve with L-Deprenyl compared to 80% with studies sponsored by the manufacturer. Advantages of L-Deprenyl include the lower risk of side effects and inability to cause hypoadrenocoritism. Disadvantages are the substantial cost and the comparatively longer time before improvements can be noticed compared to lysodren. Some veterinarians may use high doses of lysodren to induce hypoadrenocorticism (a deficiency of cortisone), as it is easier to treat. This is not a common method and is not used in some hospitals.
An – actinide Some actinides can exist in several oxide forms such as An2O3, AnO2, An2O5 and AnO3. For all actinides, oxides AnO3 are amphoteric and An2O3, AnO2 and An2O5 are basic, they easily react with water, forming bases:
Sources: en.wikipedia.org
Glibenclamide, also known as glyburide (U.S. English), is an antidiabetic medication used to treat type 2 diabetes. It is recommended that it be taken together with diet and exercise. It may be used with other antidiabetic medication. It is not recommended for use by itself in type 1 diabetes. It is taken by mouth. Common side effects include nausea and heartburn. Serious side effects may include angioedema and low blood sugar. It is generally not recommended during pregnancy but can be used during breastfeeding. It is in the sulfonylureas class of medications and works by increasing the release of insulin from the pancreas. Glibenclamide was discovered in 1969 and approved for medical use in the United States in 1984. It is available as a generic medication. In 2021, it was the 214th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
On 13 May 1983, two peat workers at Lindow Moss, Andy Mould and Stephen Dooley, noticed an unusual object—about the size of a football—on the elevator taking peat to the shredding machine. They removed the object for closer inspection, joking that it was a dinosaur egg. Once the peat had been removed, their discovery turned out to be a decomposing, incomplete human head with one eye and some hair intact. Forensics identified the skull as belonging to a European woman, probably aged 30–50. Police initially thought the skull was that of Malika Reyn-Bardt, who had disappeared in 1960 and was the subject of an ongoing investigation. While in prison on another charge, her husband, Peter Reyn-Bardt, had boasted that he had killed his wife and buried her in the back garden of their bungalow, which was on the edge of the area of mossland where peat was being dug. The garden had been examined but no body was found. When Reyn-Bardt was confronted with the discovery of the skull from Lindow Moss, he confessed to the murder of his wife. The skull was later radiocarbon dated, revealing it to be nearly 2,000 years old. "Lindow Woman", as it became known, dated from around 210 AD. This emerged shortly before Reyn-Bardt went to trial, but he was convicted on the evidence of his confession.
Below is a table of amino acids produced and identified in the "classic" 1952 experiment, as analyzed by Miller in 1952 and more recently by Bada and collaborators with modern mass spectrometry, the 2008 re-analysis of vials from the volcanic spark discharge experiment, and the 2010 re-analysis of vials from the H2S-rich spark discharge experiment. While not all proteinogenic amino acids have been produced in spark discharge experiments, it is generally accepted that early life used a simpler set of prebiotically-available amino acids.
In medicine, collateralization, also vessel collateralization and blood vessel collateralization, is the growth of a blood vessel or several blood vessels that serve the same end organ or vascular bed as another blood vessel that cannot adequately supply that end organ or vascular bed sufficiently. Coronary collateralization is considered a normal response to hypoxia and may be induced, under some circumstances, by exercise. It is considered to be protective. Collateral or anastomotic blood vessels also exist even when blood supply is adequate to an area, and these blood vessels are often taken advantage of in surgery. Some notable areas where this occurs include the abdomen, rectum, knee, shoulder, and head.
The 15N HSQC is normally the first heteronuclear spectrum acquired for the assignment of resonances where each amide peak is assigned to a particular residue in the protein. If the protein is folded, the peaks are usually well-dispersed, and most of the individual peaks can be distinguished. If there is a large cluster of severely overlapped peaks around the middle of the spectrum, that would indicate the presence of significant unstructured elements in the protein. In such cases where there are severe overlap of resonances the assignment of resonances in the spectra can be difficult. The assignment of the HSQC spectrum requires other experiments, ideally using triple resonance experiments with 15N and 13C-labelled proteins, that provide sequential connectivities between residues so that the resonances can be linked to particular residues and sequentially assigned. The assignment of the spectrum is essential for a meaningful interpretation of more advanced NMR experiments such as structure determination and relaxation analysis. Chemicals labelled with 15N isotope are relatively inexpensive, and the 15N HSQC is a sensitive experiment whereby a spectrum can be acquired in a relatively short time, the 15N HSQC is therefore often used to screen candidates for their suitability for structure determination by NMR, as well as optimization of the sample conditions. The time-consuming process of structure determination is usually not undertaken until a good HSQC spectrum can be obtained.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.